PepGen
Develops peptide-enabled oligonucleotide therapies with a clinical focus on myotonic dystrophy type 1.
Something off on this page? Send us feedback.
Profile
Develops peptide-enabled oligonucleotide therapies for serious genetic neuromuscular and neurological diseases. Its active clinical focus is PGN-EDODM1 for myotonic dystrophy type 1, with no approved products or product-sales revenue.
Develops peptide-enabled oligonucleotide therapies for serious genetic neuromuscular and neurological diseases. The EDO platform pairs proprietary peptides with oligonucleotides to improve cellular uptake and nuclear delivery.
PGN-EDODM1, for myotonic dystrophy type 1, is the active clinical focus after development of the DMD candidate PGN-EDO51 ceased. The delivery technology originated in research at the University of Oxford and the MRC Laboratory of Molecular Biology.
Founded to develop the licensed delivery approach created from this research, the organization has no approved products or product-sales revenue. The FREEDOM2 trial is subject to an FDA partial hold tied to previously submitted preclinical pharmacology and toxicology studies, while sites outside the United States remained active. Research and clinical development define the operating model.
Company facts
Key statistics
Year to date −57.0% · Average volume (30d) 939.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| May 13, 2026 | Wedbush | Reiterate | Outperform | $9 | $4 | |
| Feb 18, 2026 | Guggenheim | Reiterate | Buy | $7 | ||
| Oct 28, 2025 | H.C. Wainwright | Target | $26 | $18 | ||
| Sep 25, 2025 | Stifel Nicolaus | Target | $12 | |||
| Sep 25, 2025 | Wedbush | Reiterate | Outperform | $9 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.28 | −$0.26 | +8.6% | — | — | — | +21.72% |
| May 12, 2026Q1 FY26 | −$0.31 | −$0.26 | +16.1% | — | — | — | +5.95% |
| Mar 4, 2026Q4 FY25 | −$0.40 | −$0.27 | +32.5% | — | — | — | −18.49% |
| Nov 12, 2025Q3 FY25 | −$0.63 | −$0.52 | +17.5% | — | — | — | −4.68% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | −$339.0K | −$1.1M | −$319.0K | $0 | |
| Operating income | −$31.3M | −$23.9M | −$18.7M | −$19.7M | −$18.9M | −$18.9M | |
| Net income | −$30.2M | −$23.1M | −$18.0M | −$18.3M | −$17.8M | −$17.8M | |
| Diluted EPS | −$0.92 | −$0.70 | −$0.55 | −$0.43 | −$0.26 | −$0.26 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $117.2M · Total debt $16.1M · Total assets $141.4M · Shareholders' equity $119.5M
Dividends
No dividends on record.
Ownership
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 69.17M · Float 36.05M · 52.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 20.06M | 29.01% | 13F | May 15, 2026 |
| Oxford Science Enterprises plc · other: Former 10% Owner | 4.96M | 7.16% | Form 4 | Oct 1, 2025 |
| Commodore Capital LP | 4.48M | 6.50% | 13G | May 15, 2026 |
| Viking Global Investors LP | 3.48M | 5.03% | 13G | May 15, 2026 |
| Laurion Capital Management LP | 2.75M | 3.98% | 13F | May 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 21, 2026 | Kasra Kasraian | officer: Chief Technical Officer | −1,233 | $1.41 |
| Mar 4, 2026 | James G. McArthur | director, officer: President and CEO | −5,275 | $6.23 |
| Mar 4, 2026 | Noel Donnelly | officer: Chief Financial Officer | −2,084 | $6.23 |
| Mar 4, 2026 | Paul Streck | officer: EVP, Head of R&D | −1,879 | $6.23 |
| Sep 30, 2025 | Oxford Science Enterprises plc | other: Former 10% Owner | +200,000 | $3.20 |
Peers
- Novartis (ADR)
DMPK-targeting siRNA therapy in Phase 3 DM1 testing
- Dyne Therapeutics
DMPK-targeting Fab-ASO program in registrational DM1 development
- Vertex Pharmaceuticals
Peptide-linked oligonucleotide therapy in Phase 1/2 DM1 testing
- Arrowhead Pharmaceuticals
RNAi therapy in Phase 1/2 development for DM1
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| PepGen | $3.08 | −0.16% | $213.0M | — | — | — | — |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Dyne Therapeutics | $25.07 | −0.04% | $4.68B | — | — | — | — |
| Vertex Pharmaceuticals | $540.78 | −0.17% | $137.48B | 31.5 | 27.8 | 10.9 | +12.5% |
| Arrowhead Pharmaceuticals | $84.80 | −0.13% | $11.96B | — | — | 17.9 | +171.0% |
| Median | 27.4 | 22.1 | 10.9 | +12.5% |